DiaCarta Helps Communities Scale Up Their MPOX Testing Efforts with Its Simple, Reliable, and FDA-EUA-Approved MPOX Testing Kits
DiaCarta, Inc., an experienced in-vitro diagnostics (IVD) company that provided COVID-19 testing kits during the global pandemic, has expanded its focus to mpox detection and the detection of other infectious diseases.
As the demand for mpox (previously known as monkeypox) detection has surged following the World Health Organization (WHO) declaring a public health emergency of international concern (PHEIC) for the mpox outbreak, DiaCarta is working with distributors and laboratories to get their mpox testing kits into the hands of more doctors and hospitals around the globe so they can detect and treat patients faster.
DiaCarta’s mpox test, which received FDA Emergency Use Authorization (EUA) status in early 2023, can accurately detect the latest mpox-virus variants (clade I and clade II) with highest sensitivity and is the ONLY mpox test with FDA EUA approval that works with the same, popular qPCR machines utilized for COVID-19 testing—allowing laboratories to test their mpox samples without the cost of additional machinery or instrumentation.
Adam (Aiguo) Zhang, CEO of DiaCarta, highlighted the significance of their mpox testing kit. “We are grateful to be able to step up again—this time to take on mpox—and work with global laboratories, distributors, and hospitals to get our FDA-EUA-approved mpox testing kits in front of more doctors and patients,” Adam stated. “We are eager to continue collaborating with those on the front lines of this ongoing global health crisis—we welcome distributors, laboratories, and public health authorities from around the world to contact us and rapidly scale up their mpox testing efforts.”
Latest Mpox Statistics: New mpox cases in Africa have risen by 160% in 2024, with related deaths increasing by 19% compared to the previous year. While the majority of deaths have occurred in the Democratic Republic of Congo, the disease has also spread to 13 other African countries, and—most recently—to European and Asian nations.
About DiaCarta:
DiaCarta is a molecular in-vitro diagnostics (IVD) company that has developed innovative technologies that transform patient care by providing effective precision diagnostics using liquid biopsy. Its novel XNA technology provides a high level of sensitivity as it binds to the wild-type sequence, which enables only the mutant target sequence to be amplified. Its SuperbDNA™ technology provides a high level of detection as it amplifies the signal and requires no RNA/DNA extraction or amplification. Based in Pleasanton, California, the company is ISO-certified, GMP-compliant, and offers CLIA-certified laboratory services to its customers. www.diacarta.com
Please send all inquiries to:
(510) 878 6662
information@diacarta.com
SOURCE DiaCarta Inc
DiaCarta and Capstone Health Alliance Collaborate to Bring Revolutionary Diagnostic Tests to Enhance Patient Care
DiaCarta, Inc., a pioneer in developing innovative molecular technologies to transform patient care by providing effective precision diagnostics using liquid biopsy in cancer and infectious diseases has established a strategic collaboration with Capstone Health Alliance, one of the largest regional group purchasing organizations (GPO) in the US healthcare sector. This new collaboration brings together powerful technologies to enhance patient care.
Florida Selects DiaCarta’s cfDNA Test (RadTox™) for Statewide Use to Detect Early Response of Cancer Treatment
DiaCarta, a leading molecular diagnostics company specializing in personalized patient care through liquid biopsy, proudly announced that Florida Health Department selected “using plasma DNA concentration (DiaCarta’s RadTox™ test) for early detection of treatment response and resistance” through the Casey DeSantis Florida Cancer Innovation Fund. This fund supports deployment of the RadTox™ test throughout the State of Florida to be performed between Radiotherapy or Chemotherapy doses for real time detection of treatment response or resistance. The results will be as a real time predictor of imaging data.
DiaCarta Announces That the Oncuria® Bladder Cancer Tests Receive Medicare Coverage Effective January 1, 2024
DiaCarta proudly announced that the Oncuria® Bladder Cancer Tests, developed by Nonagen Bioscience and validated by DiaCarta as a Lab Developed Test (LDT), at its CAP-accredited and CLIA-certified laboratory, have received Medicare coverage effective January 1, 2024.
DiaCarta, Inc. and OncoAssure Ltd. Collaborate to Launch Prostate Cancer Lab Developed Test
DiaCarta, Inc. (“DiaCarta”), a pioneer in molecular diagnostic test development for cancer and infectious diseases, today announced that it has established a strategic collaboration with OncoAssure Ltd, an Irish medical diagnostics company. The focus of the collaboration is to commercialize OncoAssure’s groundbreaking Prostate test which is designed to identify patients with a lower risk of prostate cancer recurrence, guiding decisions on active surveillance or reduced monitoring post-treatment.
DiaCarta’s RadTox™ Test to Monitor Tumor Response Receives Medicare Coverage
DiaCarta, a leading molecular diagnostics company personalizing patient care through liquid biopsy, proudly announced that its revolutionary RadTox™ test, designed for tumor response monitoring, is now eligible for reimbursement from Medicare, effective January 1, 2024.